Immucell 

€5.35
2
-€0.1-1.83% Thursday 06:07

Statistics

Day High
5.35
Day Low
5.35
52W High
6.25
52W Low
3.94
Volume
-
Avg. Volume
-
Mkt Cap
48.4M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

20MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.31
-0.15
0
0.16
Expected EPS
N/A
Actual EPS
N/A

Financials

-8.05%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
50.31MRevenue
-4.05MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IUL.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Zoetis
ZTS
Mkt Cap51.98B
Zoetis is a global leader in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines, competing directly with Immucell's focus on bovine and dairy health products.
Elanco Animal Health
ELAN
Mkt Cap11.47B
Elanco Animal Health Incorporated operates in the same sector, providing a range of health products for animals, which puts it in direct competition with Immucell's product offerings.
Idexx Laboratories
IDXX
Mkt Cap45.35B
IDEXX Laboratories, Inc. specializes in diagnostics and software for pets, livestock, and poultry, overlapping with Immucell's market in animal health diagnostics.
Phibro Animal Health
PAHC
Mkt Cap1.76B
Phibro Animal Health Corporation offers a broad range of animal health and nutritional products, competing in the same space as Immucell, especially in the area of health products for livestock.
Merck
MRK
Mkt Cap298.84B
Merck & Co., Inc., through its animal health division, produces vaccines and health products for animals, making it a competitor in the animal health sector alongside Immucell.
Pfizer
PFE
Mkt Cap161.09B
Pfizer Inc., with its portfolio of animal health products through Zoetis, competes in the same industry, offering similar products for animal care and health.
Abbott Laboratories
ABT
Mkt Cap178.76B
Abbott Laboratories, while primarily focused on human healthcare, also offers veterinary products that compete in the broader market of animal health, overlapping with Immucell's market.
Novartis
NVS
Mkt Cap297.32B
Novartis International AG, through its operations in animal health, competes in the global market for veterinary products, including those offered by Immucell.

About

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Show more...
CEO
Ms. Bobbi Jo Brockmann
Employees
77
Country
DE
ISIN
US4525253062
WKN
000885825

Listings

0 Comments

Share your thoughts

FAQ

What is Immucell stock price today?
The current price of IUL.F is €5.35 EUR — it has decreased by -1.83% in the past 24 hours. Watch Immucell stock price performance more closely on the chart.
What is Immucell stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Immucell stocks are traded under the ticker IUL.F.
Is Immucell stock price growing?
IUL.F stock has fallen by -1.83% compared to the previous week, the month change is a -0.93% fall, over the last year Immucell has showed a +15.8% increase.
What is Immucell market cap?
Today Immucell has the market capitalization of 48.4M
When is the next Immucell earnings date?
Immucell is going to release the next earnings report on May 20, 2026.
What is Immucell revenue for the last year?
Immucell revenue for the last year amounts to 50.31M EUR.
What is Immucell net income for the last year?
IUL.F net income for the last year is -4.05M EUR.
How many employees does Immucell have?
As of April 07, 2026, the company has 77 employees.
In which sector is Immucell located?
Immucell operates in the Health Care sector.
When did Immucell complete a stock split?
Immucell has not had any recent stock splits.
Where is Immucell headquartered?
Immucell is headquartered in Portland, DE.